Chemotherapy + Anakinra in Patients With Pancreatic Adenocarcinoma (PDAC)

Summary

Based on a central role of inflammation in pancreas cancer, the role of IL 1 in acute and chronic inflammation , the inhibitory effect of IL 1 alfa and beta by anakinra and preliminary experience with anakinra in combination with chemotherapy in metastasis (with FOLFIRINOX) and localized disease (with gemcitabine/abraxane/cisplatin), a phase 2 study with anakinra in combination with perioperative chemotherapy for patients with PDAC is being proposed.

Timeline

Start

2021-07-23

Primary completion

2026-06

Completion

2027-06

Drugs

Indications